Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 401 - 450 out of 11,004

Document Document Title
WO/2011/145669A1
Disclosed are the compound represented by formula (I) which is useful as a therapeutic or prophylactic agent for various partial and/or generalized epileptic seizures, or a salt thereof. [In the formula, ring A and ring B independently r...  
WO/2011/144992A1
A polymer electrolyte includes a fluorine-containing structure having an alicyclic 1,3-disulfonimide in a principal chain or side chain of the polymer. A battery includes the polymer electrolyte. An imide monomer is able to introduce a f...  
WO/2011/120926A1
A description is given of 4-cyclopropyl-2-[(5-oxo-4,5-dihydro-1,2,4-triazol-1‑yl)(th io)carbonyl­aminosulfonyl]benzoic acid derivatives of the general formula (I) and salts thereof, in which the respective substituents have the defini...  
WO/2011/119560A1
The present invention relates to a mixture of polyfluoroalkylsulfonamido alkyl amines including at least one polyfluoroalkylsulfonamido alkyl amine and its analog, a di(polyfluoroalkylsulfonamido alkyl) amine. The invention also relates ...  
WO/2011/119551A1
The present invention relates to a polyfluoroalkylsulfonamido alkyl halide intermediate. The invention also relates to the use of the aforementioned halide intermediate to prepare a mixture of polyfluoroalkylsulfonamido alkyl amines incl...  
WO/2011/119555A1
The present invention relates to aminosulfonate and aminocarboxylate compositions derived from a mixture of polyfluoroalkylsulfonamido alkyl amines including at least one polyfluoroalkylsulfonamido alkyl amine and its analog, a di(polyfl...  
WO/2011/119345A3
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti apoptotic Bcl-2 protein.  
WO/2011/119345A2
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti apoptotic Bcl-2 protein.  
WO/2011/113925A3
The invention relates to methods for producing organic compounds comprising at least one functional group, in particular carboxylic acids, alcohols, esters, amides, ketones, aldehydes or amines, and to compounds for the production thereo...  
WO/2011/108690A1
The disclosed composition containing a compound represented by general formula (I) (refer to the Description for the definitions of the symbols used in the formula), or a salt thereof, has excellent CaSR agonist effects and provides phar...  
WO/2011/107705A1
The present invention relates to ketobenzofuran derivatives of the general formula (D) shown below, as well as to a method for synthesising same by coupling a quinonimine and an enaminone by a Nenitzescu reaction and to the intermediates...  
WO/2011/108724A1
An object is to provide a CaSR agonist agent that has excellent CaSR agonist effects, and particularly, a pharmaceutical product that can prevent or remedy diabetes or obesity by the effect of CaSR activation. The aforementioned object i...  
WO/2011/104127A1
The invention pertains to a compound generating an acid of the formula (I) or (II), for instance corresponding sulfonium and iodonium salts, as well as corresponding sulfonyloximes, Formula (I) and Formula (II), wherein X is CH2 or CO; Y...  
WO/2011/098610A1
A carbonic anhydrase IX (CA IX) inhibitor which comprises a compound of general formula: R-NH-CX-NH-(CH2)n-Ar-Q-SO2-NH2 or a pharmaceutically-acceptable salt, derivative or prodrug thereof; wherein n = 0, 1 or 2; Q is O or NH; X is O or ...  
WO/2011/088561A1
The present disclosure provides novel compounds as well as uses, methods, and compositions of treating, or reducing the risk of, HIV-infection.  
WO/2011/087717A1
Fluorinated arylene-containing compounds and fluorinated polymers formed from fluorinated arylene-containing compounds, and methods are described. Fluorinated polymers formed from fluorinated arylene-containing compound can be used to pr...  
WO/2011/084991A3
Fluorinated deacetylase inhibitors of the general formulae (I), (II), and (III): and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are use...  
WO/2011/083275A1
The invention relates to pyridine-pyridinone derivatives of general formula (I), where R1, R2, R3, R4, n, n', V, W, Y, Z and Ar are as defined in the description, as well as to methods for preparing the same and to the therapeutic uses t...  
WO/2011/079439A1
The present invention relates to a kind of novel carbene ligands and corresponding new ruthenium catalysts, which are highly active and selective for ROMP and RCM reactions. It discloses the significant electronic effect of different sub...  
WO/2011/078101A1
Provided is an adamantanamine derivative useful as an important intermediate for a 11βHSD-1 inhibitor. The adamantanamine derivative is represented by general formula (II) [wherein R10 is a group represented by the general formula: -(CR...  
WO/2011/071951A2
The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions....  
WO/2011/071947A2
The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invent...  
WO/2011/071951A3
The invention provides certain N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions....  
WO/2011/071947A3
The invention provides certain bis-acylated hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the invent...  
WO/2011/067266A1
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...  
WO/2011/067174A1
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing...  
WO/2011/065502A1
Disclosed are: a method for producing a fluorosulfonyl imide salt, which is capable of reducing the impurity content and can be continuously performed for a long time; and a fluorosulfonyl imide salt. The fluorosulfonyl imide salt has a ...  
WO/2011/061590A1
The present invention relates to carboxamide derivatives of Formula (I), where B1, B2, X, L, n, R, R1, R2, Z1, Z2, Rx and Ry are as defined in the claims, as compounds and compositions for inhibiting Human Immunodeficiency Virus (HIV) an...  
WO/2011/058154A1
Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing ...  
WO/2011/055142A2
The invention provides 1,4-quinones, 1,4-naphthoquinones and their sulphur analogues as inhibitors of hNAT1, an enzyme which is both a diagnostic marker and drug target for breast cancer. Some of the compounds of the invention are also c...  
WO/2011/055142A3
The invention provides 1,4-quinones, 1,4-naphthoquinones and their sulphur analogues as inhibitors of hNAT1, an enzyme which is both a diagnostic marker and drug target for breast cancer. Some of the compounds of the invention are also c...  
WO/2011/052601A1
Provided are a novel ionic organic compound represented by general formula (I), which is effective as a carbon nanotube dispersant, and a method for producing said compound by means of simple processes. (In the formula, R1, R2, and R3 re...  
WO/2011/048004A1
This invention relates to compounds of formula I, their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevent...  
WO/2011/047795A1
The present invention relates to substituted benzosulphonamide compounds of general formula (I) : in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and ...  
WO/2011/047788A1
The present invention relates to substituted benzosulphonamide compounds of general formula (I) : in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and ...  
WO/2011/048152A1
The present invention relates to novel lithium salts which comprise pentafluorophenylamide anions and are of the general formula Li+[N(SO2-R)(C6F5)]-, which are optionally present as solvent-free complexes. R is selected from fluorine, l...  
WO/2011/046793A1
A compound of Formula (I), wherein Ra is linear or branched F(CF2)n(CH2CF2)m-, or linear or branched F(CF2)o interrupted by 1 to 6 catenary oxygen atoms, each oxygen bonded to two carbon atoms, m is 1 to 4, n is 2 to 6, o is 2 to 7, A is...  
WO/2011/046795A1
|A method of providing a surface effect to a medium or substrate comprising contacting the medium or substrate with a compound of formula (I) : wherein Ra is linear or branched F(CF2)n(CH2CF2)m-, or linear or branched F(CF2)r-O-B-; B is ...  
WO/2011/046954A1
The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseas...  
WO/2011/043456A1
Disclosed is a compound represented by formula (I) or the like, which has a PAI-1 inhibitory effect. (In the formula, R1 represents an optionally substituted C6-10 aryl group or the like; R2 represents an optionally substituted C6-10 ary...  
WO/2011/043519A3
The present invention relates to sulfonamide derivatives as a serotonin receptor antagonist and serotonin reuptake inhibitor and a pharmaceutically acceptable salt thereof. The sulfonamide derivatives have serotonin 5-HT2A and 5-HT2C rec...  
WO/2011/043519A2
The present invention relates to sulfonamide derivatives as a serotonin receptor antagonist and serotonin reuptake inhibitor and a pharmaceutically acceptable salt thereof. The sulfonamide derivatives have serotonin 5-HT2A and 5-HT2C rec...  
WO/2011/033518A1
The present invention concerns a family of sulfanilamide derivatives of formula (I) as anticonvulsant agents, where R1 is selected from optionally substituted C4-C9 alkyl, optionally substituted C6-C10 aryl, optionally substituted C6-C10...  
WO/2011/034078A1
Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease. As the results of intensive studies on compoun...  
WO/2011/029842A1
The present invention includes novel compound and methods of treating a disease or disorder by antagonizing Bcl-2 family proteins, particularly compounds of Formula (I) or pharmaceutically acceptable salt thereof, as well as methods of t...  
WO/2011/027867A1
Provided is a method for producing bis(sulfonyl)imide ammonium salts, bis(sulfonyl)imide, and bis(sulfonyl)imide lithium salts in a simple manner and with good yield. A method for producing bis(sulfonyl)imide ammonium salts, wherein ammo...  
WO/2011/026778A3
The invention relates to a method and a device for producing alkylamines and alkylamine derivatives from alkanes. According to the invention, at least one boric acid is reacted with at least one alkane with the addition of energy in the ...  
WO/2011/026682A1
The invention relates to immobilized rhodium (III), ruthenium (II), or iridium (III) catalysts for asymmetric hydrogenation reactions.  
WO/2011/025982A3
The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composi...  
WO/2011/016050A3
The present invention relates to novel compounds of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvat...  

Matches 401 - 450 out of 11,004